FDA Pulls Plug on 1970s Hormone Combo Tablets at Last
Published Date: 5/27/2026
Notice
Summary
The FDA just announced that certain estrogen-androgen combo drugs, like Syntest D.S. and Syntest H.S., aren’t proven effective and can’t be sold unless they have official approval. This affects drug makers and sellers who must stop interstate shipments of these products by June 26, 2026. If you’re involved, it’s time to get compliant or say goodbye to these meds on the market!
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Manufacturers Must Stop Interstate Shipments
If you make or sell estrogen-androgen fixed-combination drugs (including Syntest D.S., Syntest H.S., Estratest, and Estratest HS, and any identical, related, or similar products covered by DESI 7661), you cannot ship them in interstate commerce unless they are the subject of an approved NDA or ANDA. That prohibition is unlawful to violate as of June 26, 2026, and FDA says it will take enforcement action without further notice against firms that continue to manufacture or ship unapproved products.
Users May Lose Access; Products Found Ineffective
The FDA found that estrogen-androgen fixed-combination products covered by DESI 7661 are not shown to be effective for the labeled menopausal use and cannot be legally shipped without FDA approval. If you take Syntest D.S., Syntest H.S., Estratest, Estratest HS, or a similar unapproved product, you may face reduced availability of those medicines after June 26, 2026, while the safety/effectiveness status and approval are resolved.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10477 — Renewal of Agency Information Collection Activities: Submission for OMB Review; Comment Requested; Containerized Freight Statistics-Imports and Exports; 3072-0074
The Federal Maritime Commission is asking to keep collecting info on container ship imports and exports, but with some updates. Shipping companies and related businesses should take note and can share their thoughts by June 26, 2026. This helps the government keep track of trade without adding extra hassle or costs.
Next: 2026-10482 — Agency Information Collection Activity: Appointment of Veterans Service Organization as Claimant's Representative and Appointment of Individual as Claimant's Representative
The VA is updating forms that let veterans pick someone to help with their claims, like a Veterans Service Organization or an individual. They want your feedback by July 27, 2026, to make sure the forms are clear and easy to use. This update won’t cost veterans extra money but aims to speed up and improve the claims process.